Administration of human urinary colony stimulating factor after bone marrow transplantation. 1988

T Masaoka, and K Motoyoshi, and F Takaku, and S Kato, and M Harada, and Y Kodera, and A Kanamaru, and Y Moriyama, and R Ohno, and M Ohira
Center for Adult Disease, Osaka, Japan.

A phase II study of the use of colony stimulating factor derived from human urine (CSF-HU) was performed after bone marrow transplantation (BMT). Steady and rapid recovery of leukocyte and granulocyte numbers was observed. In most patients who received CSF-HU from day 1, leukocyte numbers started to increase on day 6 and monocytes and granulocytes on day 11. Significant differences in the days to recovery of leukocytes over 1 x 10(9)/l and of granulocytes over 0.5 x 10(9)/l were observed in comparison with non-randomized control patients. In some patients in whom recovery of leukocytes was delayed, CSF also seemed to be effective in increasing leukocyte numbers from 8 days after the start of administration. There was no significant difference in the rate of relapse of leukemia between the two groups. CSF-HU seems very promising as a treatment of patients after BMT by shortening the period of leukopenia or granulocytopenia.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003115 Colony-Stimulating Factors Glycoproteins found in a subfraction of normal mammalian plasma and urine. They stimulate the proliferation of bone marrow cells in agar cultures and the formation of colonies of granulocytes and/or macrophages. The factors include INTERLEUKIN-3; (IL-3); GRANULOCYTE COLONY-STIMULATING FACTOR; (G-CSF); MACROPHAGE COLONY-STIMULATING FACTOR; (M-CSF); and GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; (GM-CSF). MGI-1,Macrophage-Granulocyte Inducer,Colony Stimulating Factor,Colony-Stimulating Factor,MGI-1 Protein,Myeloid Cell-Growth Inducer,Protein Inducer MGI,Cell-Growth Inducer, Myeloid,Colony Stimulating Factors,Inducer, Macrophage-Granulocyte,Inducer, Myeloid Cell-Growth,MGI 1 Protein,MGI, Protein Inducer,Macrophage Granulocyte Inducer,Myeloid Cell Growth Inducer

Related Publications

T Masaoka, and K Motoyoshi, and F Takaku, and S Kato, and M Harada, and Y Kodera, and A Kanamaru, and Y Moriyama, and R Ohno, and M Ohira
November 1996, Chinese medical journal,
T Masaoka, and K Motoyoshi, and F Takaku, and S Kato, and M Harada, and Y Kodera, and A Kanamaru, and Y Moriyama, and R Ohno, and M Ohira
September 1994, Blood,
T Masaoka, and K Motoyoshi, and F Takaku, and S Kato, and M Harada, and Y Kodera, and A Kanamaru, and Y Moriyama, and R Ohno, and M Ohira
July 1988, Lancet (London, England),
T Masaoka, and K Motoyoshi, and F Takaku, and S Kato, and M Harada, and Y Kodera, and A Kanamaru, and Y Moriyama, and R Ohno, and M Ohira
November 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
T Masaoka, and K Motoyoshi, and F Takaku, and S Kato, and M Harada, and Y Kodera, and A Kanamaru, and Y Moriyama, and R Ohno, and M Ohira
December 1992, Blood,
T Masaoka, and K Motoyoshi, and F Takaku, and S Kato, and M Harada, and Y Kodera, and A Kanamaru, and Y Moriyama, and R Ohno, and M Ohira
November 1989, Experimental hematology,
T Masaoka, and K Motoyoshi, and F Takaku, and S Kato, and M Harada, and Y Kodera, and A Kanamaru, and Y Moriyama, and R Ohno, and M Ohira
August 1988, Behring Institute Mitteilungen,
T Masaoka, and K Motoyoshi, and F Takaku, and S Kato, and M Harada, and Y Kodera, and A Kanamaru, and Y Moriyama, and R Ohno, and M Ohira
November 1994, Bone marrow transplantation,
T Masaoka, and K Motoyoshi, and F Takaku, and S Kato, and M Harada, and Y Kodera, and A Kanamaru, and Y Moriyama, and R Ohno, and M Ohira
January 1990, Haematology and blood transfusion,
T Masaoka, and K Motoyoshi, and F Takaku, and S Kato, and M Harada, and Y Kodera, and A Kanamaru, and Y Moriyama, and R Ohno, and M Ohira
December 1989, Japanese journal of clinical oncology,
Copied contents to your clipboard!